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http://dx
3092Objective: Patients presenting with acute coronary syndrome (ACS) are treated with dual antiplatelet agents,
including aspirin and clopidogrel, to prevent mortality and recurrent ischemia. However, those who require
coronary artery bypass grafting (CABG) could have increased postoperative bleeding and bleeding-related
adverse outcomes. The current guidelines on clinical management differ significantly. The present
meta-analysis examined the evidence for clopidogrel in the treatment of patients presenting with ACS requiring
CABG, with a focus on the timing of medication cessation before surgery.
Methods: A systematic review of 9 electronic databases was performed to identify all relevant studies with
comparable outcomes for patients with ACS treated with clopidogrel before CABG. The endpoints included
reoperation, major bleeding, mortality, and a composite endpoint of mortality and recurrent myocardial
infarction.
Results: Five relevant studies were identified according to the predefined selection criteria. Patients who had
received clopidogrel had a significantly lower incidence of composite endpoints than those who had not.
However, patients who underwent CABG<5 days after the last dose of clopidogrel had a significantly greater
incidence of reoperation, major bleeding, and combined adverse outcomes than those who had had a washout
period>5 days.
Conclusions: The results from the present meta-analysis suggest that patients who present with ACS should be
treated with dual antiplatelet therapy, including clopidogrel. However, for patients subsequently referred for
CABG, a minimum washout period of 5 days should be observed to minimize perioperative bleeding and
bleeding-related complications, unless emergency indications exist. These results differ from those of previous
studies and guidelines. (J Thorac Cardiovasc Surg 2014;148:3092-8)See related commentary on pages 3099-100.Acute coronary syndrome (ACS) is commonly associated
with atherosclerotic plaque rupture, which can be followed
by platelet activation and subsequent coronary occlusion due
to thrombus formation. To prevent potentially fatal sequelae,
antiplatelet medications are routinely administered to
patients presenting with ACS. However, the prescription of
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The Journal of Thoracic and Cardiovascular Surraised concerns of increased postoperative bleeding since the
beginning of cardiac surgery in the late 1970s.1,2 With
pharmacologic evolution and development, an exponential
growth has occurred in the prescription of antiplatelet
agents during the past decade. Some of the most commonly
prescribed modern antiplatelet agents function as P2Y12
adenosine diphosphate receptor antagonists, including
clopidogrel, prasugrel, and ticagrelor. Despite being one of
the most prevalent drugs internationally, the prescribing
pattern of clopidogrel for patients presenting with ACS
has remained heterogeneous in clinical practice, in
particular, for those who might require subsequent surgical
revascularization.
At the crux of the dilemma concerning antiplatelet
therapy in relation to CABG is the risk of postoperative
bleeding and bleeding-related complications weighed
against the potential benefits of the mortality and
ischemic events prevented by preoperative anticoagulation.
Proponents of aggressive dual antiplatelet therapy have
emphasized the benefits derived from reduced mortality
and recurrent myocardial infarction at no additional risk
to perioperative bleeding.3,4 However, others have
cautioned against this regimen for patients undergoinggery c December 2014
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MCABG, citing clinical and economic outcomes.5 Despite the
vast quantity of research, major disagreements remain
owing to the conflicting data. Furthermore, the guidelines
from various international medical associations have
presented different recommendations, further hindering
the decision-making process for clinicians.6-10 We
examined the current clinical evidence for the use of
clopidogrel in the treatment of patients presenting with
ACS and requiring CABG, with a specific focus on the
timing of medication cessation before CABG.
METHODS
Literature Search Strategy
Electronic searches were performed on OVIDMedline, EMBASE, ACP
Journal Club, Database of Abstracts of Reviews of Effects, Cochrane
Database of Systematic Reviews, Health Technology Assessment,
Cochrane Methodology Register, NHS Economic Evaluation Database,
and Cochrane Central Register of Controlled Trials from their date of
inception to March 2013. The search strategy included a combination of
‘‘clopidogrel’’ or ‘‘iscover’’ or ‘‘plavix’’ and ‘‘coronary artery bypass
grafting’’ or ‘‘coronary artery surgery’’ or ‘‘coronary artery graft surgery’’
or ‘‘CABG’’ and ‘‘bleeding’’ or ‘‘haemorrhage’’ or ‘‘hemorrhage’’ as either
keywords or MeSH headings. The reference lists of all retrieved studies
were reviewed for additional identification of potentially relevant studies.
All relevant studies identified were assessed with application of the
predefined selection criteria.
Selection Criteria and Data Extraction
The selected studies for the present meta-analysis included those that
provided data on comparative bleeding outcomes for patients presenting
with ACS who had been treated with clopidogrel before CABG. To match
comparable endpoints, only studies with data on clopidogrel cessation at
<5 or >5 days before CABG were included. When institutions had
published duplicate trials, only the most updated reports were included
for quantitative appraisal. The primary endpoints included major bleeding,
reoperation, all-cause mortality, and the composite endpoint of mortality
and myocardial infarction. All publications were limited to humanThe Journal of Thoracic and Carsubjects and the English language. Abstracts, case reports, conference
presentations, editorials, and expert opinions were excluded.
To standardize comparisons between the treatment groups, separate
analyses were performed to compare patients who had been treated with
clopidogrel within 5 days of CABG and thosewho had had a 5-day washout
period. Additionally, patients who had had >5 days of clopidogrel
clearance were compared with those who had not received clopidogrel at
all. Data were extracted from the text, tables, and figures of the selected
studies. Two of the investigators (P.I. and S.A.) independently reviewed
each retrieved study. Discrepancies between the 2 reviewers were resolved
by discussion and consensus with the senior investigators (C.C. and
T.D.Y.).
Statistical Analysis
The meta-analysis was performed by combining the reported
incidence of the primary endpoints. The odds ratio (OR) was used as a
summary statistic. In the present meta-analysis, the results using the
random effects model were presented account for the possible clinical
diversity and methodologic variation among the studies. Chi-square
tests were used to study the heterogeneity among the trials. The I2
statistic was used to estimate the percentage of total variation across the
studies, resulting from heterogeneity rather than chance. The I2 can be
calculated as I2 ¼ 100% 3 (Q  df)/Q, with Q defined as Cochrane’s
heterogeneity statistics and df as the degree of freedom. An I2
value >50% was considered substantial heterogeneity. If substantial
heterogeneity was present, the possible clinical and methodologic
reasons for this were explored qualitatively. Sensitivity analysis was
performed by testing both fixed and random effect models. All P values
were 2-sided. All statistical analyses were conducted using Review
Manager, version 5.1.2 (Cochrane Collaboration, Software Update,
Oxford, United Kingdom).RESULTS
Quantity and Quality of Trials
A total of 700 references were identified through the 9
electronic database searches, with 6 additional records
identified through other sources. After exclusion of
duplicate references, 504 potentially relevant studies
were retrieved. After a detailed evaluation of these studies,
41 remained for assessment. After applying the selection
criteria, 5 studies were selected for quantitative assessment
and meta-analysis.4,5,11-13 Of these 5 reports, 1 was a
randomized controlled trial (RCT) comparing clopidogrel
until 5 days before CABG versus clopidogrel up to
the point of surgery.13 Three studies were subgroup
analyses of RCTs comparing clopidogrel versus no
clopidogrel,4,11,12 and one was a large multi-institutional
observational study.5 The data presented from these 5
reports included 6385 patients with coronary artery disease
who had presented with ACS and subsequently underwent
CABG. Of these, 2632 had been treated with clopidogrel
and 3753 had not. An overview of the search strategy
is presented in Figure 1, and a summary of the study
characteristics is presented in Table 1.ClopidogrelWashout>5 Days Versus No Clopidogrel
When the 873 patients who had been prescribed
clopidogrel with a washout period of >5 days beforediovascular Surgery c Volume 148, Number 6 3093
FIGURE 1. Summary of search strategy performed to identify all relevant studies for meta-analysis of clopidogrel before coronary artery bypass grafting.
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MCABG were compared with the corresponding 1413
patients who had not, those treated with clopidogrel
demonstrated a significantly lower incidence of composite
endpoints (8.1% vs 14.1%; OR, 0.60; 95% confidence
interval [CI], 0.44-0.81; P ¼ .0008; I2 ¼ 0%; Figure 2).
The incidence of reoperation (1.5% vs 2.3%; OR, 0.51;
95% CI, 0.25-1.06; P ¼ .07; I2 ¼ 0%), all-cause mortality
(3.3% vs 3.9%; OR, 0.86; 95% CI, 0.39-1.89; P ¼ .70;
I2 ¼ 21%), and major bleeding (19.7% vs 32.3%; OR,
0.85; 95% CI, 0.67-1.07; P ¼ .17; I2 ¼ 0%) between these
2 treatment groups was not significantly different. SeparateTABLE 1. Summary of selected studies that compared bleeding outcomes
Study Study type
Publication
year
Enrolling
period Indicat
ACUITY12 RCT* 2009 2003-2005 NSTE-A
CLARITY-TIMI-284 RCT* 2007 2003-2004 STE-AC
CRUSADE5 Observational 2006 2003-2004 NSTE-A
Akowuah13 RCT 2005 2002-2003 NSTE-A
CURE11 RCT* 2004 1998-2000 NSTE-A
CABG, Coronary artery bypass grafting; OPCAG, off-pump coronary artery bypass g
RCT, randomized controlled trial; NSTE-ACS, non–ST-elevation acute coronary syndrome
in Myocardial Infarction 28; STE-ACS, ST-elevation acute coronary syndrome; NR, not repo
Adverse Outcomes With Early Implementation of the ACC/AHA [American College of C
Angina to Prevent Recurrent Events. *Retrospective subgroup analysis of larger RCT. yE
3094 The Journal of Thoracic and Cardiovascular Suranalyses using a fixed effect model did not alter the
significant statistical findings.
Clopidogrel Washout>5 Days Versus<5 Days
Of the 2632 patients presenting with ACS included in the
meta-analysis who had been prescribed clopidogrel before
CABG, 1759 had been prescribed clopidogrel <5 days
before CABG and 873 patients had had a washout period
of >5 days before CABG. When these 2 groups were
compared, patients who had >5 days of washout were
shown to have a lower incidence of reoperation (1.8% vsafter clopidogrel before CABG
ion
Urgent
CABG (%) OPCAG (%)
Clopidogrel Placebo
>5 d <5 d >5 dy <5 dy
CS 100 12.7 249 524 747
S 100 NR 31 35 32 38
CS 100 NR 113 739 180 1826
CS 100 0 24 25 NR NR
CS 48 NR 456 436 454 476
rafting; ACUITY, Acute Catheterization and Urgent Intervention Triage strategY;
; CLARITY-TIMI-28, Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis
rted; CRUSADE, Can Rapid Risk Stratification of Unstable Angina Patients Suppress
ardiology/American Heart Association] Guidelines; CURE, Clopidogrel in Unstable
ither placebo or no medication.
gery c December 2014
FIGURE 2. Forest plot of the odds ratio of the composite endpoint of mortality and myocardial infarction after>5 days clopidogrel washout versus no
clopidogrel before coronary artery bypass grafting. The estimate of the odds ratio of each trial corresponds to the middle of the squares, and the horizontal
line shows the 95% confidence interval (CI). On each line, the numbers of events as a fraction of the total number randomized are shown for both treatment
groups. For each subgroup, the sum of the statistics, along with the summary odds ratio, is represented by the middle of the solid diamonds. A test of
heterogeneity between the trials within a subgroup is given below the summary statistics. M-H, Mantel-Haenszel; ACUITY, Acute Catheterization and
Urgent Intervention Triage strategY; CLARITY-TIMI, Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis in Myocardial Infarction 28;
CRUSADE, Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA
[American College of Cardiology/American Heart Association] Guidelines; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events.
Cao et al Perioperative Management3.2%; OR, 0.47; 95% CI, 0.25-0.91; P ¼ .03; I2 = 0%;
Figure 3); a lower incidence of major bleeding (19.7% vs
30.2%; OR, 0.71; 95% CI, 0.51-0.98; P ¼ .04;
I2 ¼ 38%; Figure 4); and a lower incidence of the
composite endpoint that included mortality and
myocardial infarction,5,13 as well as recurrent ischemia,4
stroke,11 and emergency revascularization12 (7.9% vs
9.7%; OR, 0.68; 95% CI, 0.50-0.92; P ¼ .01; I2 ¼ 0%;
Figure 5). The difference in the all-cause mortality
rates between the 2 treatment groups was not
statistically significant (3.1% vs 4.0%; OR, 0.77; 95%
CI, 0.29-2.07; P¼ .61; I2¼ 47%). Separate analyses using
a fixed effect model did not alter the significant statistical
findings.
DISCUSSION
CABG remains the preferred treatment modality for
selected patients presenting with ischemic heart
disease, particularly in the context of total arterial revascu-
larization according to recent evidence.14-16 When
considering the postoperative bleeding outcomes of an
irreversible antiplatelet agent such as clopidogrel, the
timing of medication cessation before CABG isFIGURE 3. Forest plot of the odds ratio of reoperation after>5 days of clopidog
The estimate of the odds ratio of each trial corresponds to themiddle of the squar
line, the numbers of events as a fraction of the total number randomized are sho
along with the summary odds ratio, is represented by the middle of the solid diam
below the summary statistics.M-H, Mantel-Haenszel; ACUITY, Acute Catheteri
rel as Adjunctive Reperfusion Therapy–Thrombolysis in Myocardial Infarction
The Journal of Thoracic and Carparamount. Previous studies have generalized outcomes
after categorizing patients to ‘‘clopidogrel’’ versus ‘‘no
clopidogrel,’’ without emphasis on the washout
period.11,12,17 In the Acute Catheterization and Urgent
Intervention Triage strategY study, Ebrahimi and
colleagues12 reported that patients who were given
clopidogrel before CABG had a significantly reduced
30-day composite incidence of ischemia but not of
increased post-CABG major bleeding. However, when the
data were stratified according to the timing of clopidogrel
cessation before CABG, the patients who had >5 days
of washout were significantly less likely to undergo
transfusion or to develop composite ischemia compared
with patients who underwent CABG within 5 days of their
last clopidogrel dose.12 One potential explanation for this is
that the patients who underwent CABG <5 days after
clopidogrel might have represented a cohort who were at
greater risk and more unstable. However, this hypothesis
was refuted by the Can Rapid Risk Stratification of
Unstable Angina Patients Suppress Adverse Outcomes
With Early Implementation of the ACC/AHA [American
College of Cardiology/American Heart Association]
Guidelines (CRUSADE) study, which reported thatrel washout versus<5 days washout before coronary artery bypass grafting.
es, and the horizontal line shows the 95% confidence interval (CI). On each
wn for both treatment groups. For each subgroup, the sum of the statistics,
onds. A test of heterogeneity between the trials within a subgroup is given
zation and Urgent Intervention Triage strategY; CLARITY-TIMI, Clopidog-
28; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events.
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FIGURE 4. Forest plot of the odds ratio of major bleeding after>5 days of clopidogrel washout versus<5 days washout before coronary artery bypass
grafting. The estimate of the odds ratio of each trial corresponds to themiddle of the squares, and the horizontal line shows the 95% confidence interval (CI).
On each line, the numbers of events as a fraction of the total number randomized are shown for both treatment groups. For each subgroup, the sum of the
statistics, along with the summary odds ratio, is represented by themiddle of the solid diamonds. A test of heterogeneity between the trials within a subgroup
is given below the summary statistics. M-H, Mantel-Haenszel; ACUITY, Acute Catheterization and Urgent Intervention Triage strategY; CLARITY-TIMI,
Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis in Myocardial Infarction 28; CRUSADE, Can Rapid Risk Stratification of Unstable Angina
Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA [American College of Cardiology/American Heart Association]
Guidelines; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events.
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actually had a higher risk profile, including previous
revascularization, previous stroke, diabetes, renal failure,
and acute presenting features such as congestive heart
failure, tachycardia, and elevated cardiac enzymes.5 The
investigators of the CRUSADE trial hypothesized that
more stable patients might have undergone early CABG
owing to economic restraints or a lack of appreciation of
the bleeding outcomes associated with clopidogrel close
to CABG.
A number of guidelines have been published to assist
clinicians in making decisions regarding the prescription
of clopidogrel for patients who present with ACS
(Table 2). Although a relative consensus has been reached
for patients who undergo elective CABG to have a delay
of 5 to 7 days after the last clopidogrel dose, the recommen-
dations for patients who require urgent CABG are less clear.
These have ranged from a waiting period of 5 to 7 days to
continuing clopidogrel until surgery.6-10 The American
College of Cardiology Foundation/American HeartFIGURE 5. Forest plot of the odds ratio of the composite endpoint of mortality a
washout before coronary artery bypass grafting. The estimate of the odds ratio o
shows the 95% confidence interval (CI). On each line, the numbers of
both treatment groups. For each subgroup, the sum of the statistics, along
diamonds. A test of heterogeneity between the trials within a subgroup is giv
Catheterization and Urgent Intervention Triage strategY; CLARITY-TIMI, Clop
Infarction 28; CRUSADE, Can Rapid Risk Stratification of Unstable Angina
ACC/AHA [American College of Cardiology/American Heart Association] G
Events.
3096 The Journal of Thoracic and Cardiovascular SurAssociation guidelines have recommended clopidogrel
cessation for 1 day before urgent CABG and stated
that it would be reasonable to perform urgent surgery
within 5 days of clopidogrel treatment.15 Similarly, the
Society of Thoracic Surgeons has recommended a delay
of 1 or 2 days for patients requiring urgent CABG.18 In
addition, a previous meta-analysis that did not categorize
the studies according to the washout period of clopidogrel
concluded that patients presenting with ACS should
proceed to surgery without delay for a clopidogrel-free
interval.17
The present meta-analysis identified outcomes according
to the timing of clopidogrel cessation in relation to CABG.
Despite the widespread prescription of clopidogrel in the
clinical setting, it was surprising to find only 5 relevant
studies with sufficient data to analyze in the existing
literature. Similar to individual trials, we found that
patients who were given clopidogrel with >5 days
clearance before surgery had a significantly lower
composite endpoint, including mortality and myocardialndmyocardial infarction after>5 days clopidogrel washout versus<5 days
f each trial corresponds to the middle of the squares, and the horizontal line
events as a fraction of the total number randomized are shown for
with the summary odds ratio, is represented by the middle of the solid
en below the summary statistics. M-H, Mantel-Haenszel; ACUITY, Acute
idogrel as Adjunctive Reperfusion Therapy–Thrombolysis in Myocardial
Patients Suppress Adverse Outcomes With Early Implementation of the
uidelines; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent
gery c December 2014
TABLE 2. A summary of guideline recommendations for the prescription of clopidogrel for patients before coronary artery bypass grafting
Guideline Year Elective CABG Urgent CABG
Society of Thoracic Surgeons 2012 Cease ‘‘a few days’’ before
elective CABG
‘‘A delay of a day or two is reasonable’’
American College of Chest Physicians 2012 Cease 5 d No specific recommendations, anticipate use of
platelet transfusion and antifibrinolytic drugs if
clopidogrel given<5 d before CABG
American College of Cardiology Foundation/
American Heart Association
2011 Cease 5 d Cease 1 d; ‘‘reasonable to perform CABG
<5 d after clopidogrel’’
Canadian Cardiovascular Society 2009 Cease 5-7 d If at high risk of fatal ischemic event or with high-risk
coronary anatomy, continue clopidogrel; if high
ischemic risk and high bleeding risk, cease at 3-5 d
European Association for Cardio-Thoracic Surgery 2008 5-7 d ‘‘if condition allows’’ 5-7 d ‘‘if condition allows’’
CABG, Coronary artery bypass grafting.
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Minfarction, compared with patients not treated with
clopidogrel at all. These 2 groups also did not have a
statistically significant difference in the incidences of
reoperation, all-cause mortality, or major bleeding.
However, when patients with>5 days of washout were
compared with patients who underwent CABG within 5
days of clopidogrel treatment, the patients with the shorter
washout period were almost twice as likely to require
reoperation and were significantly more likely to
experience major bleeding or a combined endpoint that
included mortality, myocardial infarction, stroke, and
revascularization. These findings were not reported in the
individual trials or previous meta-analyses and underscored
the importance of categorizing patients who were allocated
to the clopidogrel group according to their duration of
medication cessation.
A number of limitations to our study should be
acknowledged, and the results should be interpreted with
caution. First, the patient inclusion criteria differed among
the studies, and the presenting features included
ST-elevation ACS and non–ST-elevation ACS. However,
the exclusion of studies involving patients with stable
coronary artery disease aimed to target a specific study
population in our analysis. Second, the surgical techniques
could have varied among institutions, and the reporting of
off-pump CABG was limited, although it has been
previously shown to result in fewer bleeding complications
for patients treated with clopidogrel.19,20 Third, the
endpoints and definitions varied among the studies,
with the composite endpoint including mortality and
myocardial infarction,5,13 as well as stroke,11 recurrent
ischemia,4 and urgent revascularization.12 However, no
significant heterogeneity was detected by our statistical
assessment.
To interpret the results reported in the present study in
the context of more novel P2Y12 receptor antagonists,
such as prasugrel, ticagrelor, and cangrelor, it is important
to acknowledge the lack of robust clinical data on the
perioperative effects of these contemporary agents afterThe Journal of Thoracic and CarCABG. The PLATelet inhibition and patient Outcomes
(PLATO) and Clopidogrel in Non–ST-Segment Elevation
Myocardial Infarction-2 (DISPERSE-2) trials compared
ticagrelor with clopidogrel but varied in their trial design
and endpoint definitions.21,22 The PLATO trial analyzed
1261 patients who had undergone CABG within 7 days
of medication cessation and concluded that patients
treated with ticagrelor had a significantly lower risk of
overall and cardiovascular death compared with
those receiving clopidogrel. However, no significant
differences were found in the incidence of major
bleeding.21 Similarly, post hoc analysis of the
DISPERSE-2 trial found a trend, but no statistical
significance, favoring ticagrelor over clopidogrel for
bleeding outcomes.22 A subgroup analysis of the Trial to
Assess Improvement in Therapeutic Outcomes by Opti-
mizing Platelet Inhibition with Prasugrel-Thrombolysis
In Myocardial Infarction 38 (TRITON-TIMI 38) study
compared patients who were prescribed prasugrel versus
clopidogrel before isolated CABG and found that
patients treated with prasugrel were more likely to
experience greater chest drain bleeding, platelet
transfusion, and reoperation but fewer perioperative
deaths.23 Finally, the BRIDGE investigators compared
cangrelor and placebo agents in a RCT of or patients
who had presented with ACS or undergone coronary
stent implantation before CABG.24 The results of that
trial suggested that the differences in major bleeding
between the 2 treatment arms were not significant, but
patients treated with cangrelor were more likely to have
minor bleeding.24 Overall, data are currently insufficient
in the published studies to quantitatively meta-analyze
novel P2Y12 inhibitors, and future RCTs assessing the
safety and efficacy of antiplatelet agents should aim
to predefine CABG-related outcomes rather than retro-
spectively performing subgroup analyses. In the present
clinical setting, patients might benefit from platelet
activity measurements that can predict increased risks of
postoperative bleeding and transfusion.25diovascular Surgery c Volume 148, Number 6 3097
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MCONCLUSIONS
The results from the present meta-analysis suggest that
patients who present with ACS should be treated with dual
antiplatelet therapy that includes clopidogrel. However, for
patients subsequently referred for CABG, a minimum
washout period of 5 days could be observed in
clinically suitable situations to minimize the incidence of
perioperative bleeding and bleeding-related complications.
Such complications include repeat sternotomy and
re-exploration, which has been associated with a 4.5-fold
increase in perioperative mortality.25 The longer duration
of preoperative hospitalization could have economic
implications for patients who need to be monitored as an
inpatient before CABG. However, evidence from our study
has suggested that they are at a lower risk of mortality and
recurrent ischemia compared with patients expedited to
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